James J. Bochnowski - Mar 31, 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAGX	Convertible Promissory Note	Purchase	$4.05B	+27K		$150,000.00^*	27K	Mar 31, 2025	Common Stock	27K	$5.56	See Footnote	F1, F3
transaction	JAGX	Warrant to Purchase Common Stock	Purchase		+27K			27K	Mar 31, 2025	Common Stock	27K	$5.43	See Footnote	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 27,002 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.
F2	As an inducement to enter into the Purchase Agreement, the reporting person received a warrant (the "Warrant") to purchase up to 27,002 shares of Common Stock with an exercise price of $5.43 per share. The Warrant is exercisable immediately upon issuance and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.
F3	Securities held directly by the Bochnowski Family Trust. Mr. Bochnowski, by virtue of his position as a co-trustee and beneficiary of such trust and his sharing of voting and investment control over the securities held by the trust with his spouse, may be deemed to beneficially own the securities held by the Bochnowski Family Trust for purposes of Section 16